| Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial P Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ... The lancet oncology 18 (3), 312-322, 2017 | 1849 | 2017 |
| Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ... Nature medicine 24 (6), 749-757, 2018 | 1156 | 2018 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1122 | 2016 |
| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 592 | 2020 |
| Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study SH Armenian, L Xu, B Ky, C Sun, LT Farol, SK Pal, PS Douglas, S Bhatia, ... Journal of Clinical Oncology 34 (10), 1122-1130, 2016 | 531 | 2016 |
| Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium DYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ... European urology 66 (4), 704-710, 2014 | 531 | 2014 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851-3858, 2017 | 491 | 2017 |
| Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ... Annals of Oncology 31 (8), 1030-1039, 2020 | 452 | 2020 |
| Triple negative breast cancer: unmet medical needs SK Pal, BH Childs, M Pegram Breast cancer research and treatment 125, 627-636, 2011 | 428 | 2011 |
| Bladder cancer PE Clark, N Agarwal, MC Biagioli, MA Eisenberger, RE Greenberg, ... Journal of the National Comprehensive Cancer Network 11 (4), 446-475, 2013 | 427 | 2013 |
| Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial RJ Motzer, PB Robbins, T Powles, L Albiges, JB Haanen, J Larkin, XJ Mu, ... Nature medicine 26 (11), 1733-1741, 2020 | 417 | 2020 |
| The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first … JJ Ko, W Xie, N Kroeger, J Lee, BI Rini, JJ Knox, GA Bjarnason, S Srinivas, ... The lancet oncology 16 (3), 293-300, 2015 | 403 | 2015 |
| Evaluating the older patient with cancer: understanding frailty and the geriatric assessment SK Pal, V Katheria, A Hurria CA: a cancer journal for clinicians 60 (2), 120-132, 2010 | 338 | 2010 |
| Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial N Dizman, L Meza, P Bergerot, M Alcantara, T Dorff, Y Lyou, P Frankel, ... Nature medicine 28 (4), 704-712, 2022 | 337 | 2022 |
| Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ... Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014 | 298 | 2014 |
| S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites J Deng, Y Liu, H Lee, A Herrmann, W Zhang, C Zhang, S Shen, ... Cancer cell 21 (5), 642-654, 2012 | 286 | 2012 |
| Akt inhibitors in clinical development for the treatment of cancer SK Pal, K Reckamp, H Yu, RA Figlin Expert opinion on investigational drugs 19 (11), 1355-1366, 2010 | 276 | 2010 |
| Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations SK Pal, JE Rosenberg, JH Hoffman-Censits, R Berger, DI Quinn, ... Cancer discovery 8 (7), 812-821, 2018 | 269 | 2018 |
| Impact of age, sex, and comorbidity on cancer therapy and disease progression SK Pal, A Hurria Journal of clinical oncology 28 (26), 4086-4093, 2010 | 267 | 2010 |
| NCCN guidelines insights: bladder cancer, version 5.2018 TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the national comprehensive cancer network 16 (9), 1041-1053, 2018 | 266 | 2018 |
Toni ChoueiriDana-Farber Cancer Institutedfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip